MedTrace Logo

Tecfidera Diffusion Tensor Imaging

NCT02686684 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2016-10-26

No results posted yet for this study

Summary

The primary aim of this study is to explore the effect of dimethyl fumarate on gray matter (GM) pathology, as measured by changes in diffusion-tensor imaging (DTI) of the thalamus in patients with relapsing multiple sclerosis (MS). The secondary objective of this study is to investigate the effect of dimethyl fumarate on evolution of microstructural changes in normal appearing white matter (NAWM), as measured by DTI.

Conditions

  • Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging

Interventions

DRUG

Dimethyl fumarate

Sponsors & Collaborators

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Robert Zivadinov, MD, PhD · BNAC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-10-31
Completion
2016-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02686684 on ClinicalTrials.gov